Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
InVivo Therapeutics Corp. (NVIV) Unique Spinal Cord Injury Technologies Wow Unserved Market, Invite Huge Strategic Relationship Momentum
A uniquely-positioned medical device developer with spinal cord injury (SCI) technologies that represent groundbreaking innovation, InVivo Therapeutics has a strong technology portfolio that has drawn significant focus of late from investors. Chief among the offerings is the Biopolymer Scaffold Device (BSD), a biodegradable and biocompatible implant (injection or surgical) designed to both mitigate secondary bleeding, inflammation, and scarring, as well as to enable localized recovery towards function via natural neuroplasticity and delimiting of the body’s own immune response to further cell death. In preclinical studies, specifically using highly-similar African green monkeys, NVIV’s brilliant approach of focusing on the underlying pathology instead of the symptoms has yielded impressive fruits, enabling paralyzed subjects able to walk again within weeks of initial treatment.
By minimizing secondary injuries and successfully promoting functional recovery, NVIV’s technologies have the potential to bring unquantifiable quality of life improvements for numerous traumatic back-injury patients and very well could pave the way to a more ubiquitous set of solutions for back injuries. NVIV is helping to move the entire state of the art forward with their innovative products and continued commitment to partnerships within the larger spine care sector.
The beauty of the NVIV approach is that because the BSD is a medical device, the FDA-approval process that normally takes years for a drug can be largely avoided. An IDE (Investigational Device Exemption) was filed with the FDA in July of 2011 and an anticipated meeting this April should suffice for a finalization of clinical trial design.
The BSD is designed to take full advantage of the research done on conducting polymers, which not only perform well for transmission of electrical signals from the CNS, but also may promote neural tissue repair, thanks to the ability of the material to integrate with CNS tissues successfully.
The reason these properties are so important is that the BSD is also designed to be commercialized in a version seeded with autologous human neural stem cells (hNSCs), with the patient’s own stem cells kick-starting the process of tissue recovery. Such partnerships as that with The Miami Project to Cure Paralysis (the most comprehensive spinal cord injury research center in the world), whose work involving Schwann cell transplantation takes full advantage of this product vector, will be key to fully leveraging the potential of the BSD framework.
The Miami Project’s initiative using injected Schwann cells also benefits significantly from NVIV’s third major offering, a biopolymer hydrogel, which is the perfect growth factor for stem cells and Schwann cells, allowing highly-localized/controlled drug release.
Needless to say this is an impressive array of acute/chronic SCI offerings in a massively underserved space for the Cambridge, MA based NVIV, who recently signed a multi-year lease on their 21k sq. ft. HQ (set to house significant lab space and cGMP cleanroom for manufacturing and packaging, in addition to the corporate offices).
Founder, CEO, CFO and Chairman of the NVIV Board, Frank Reynolds (scheduled to appear on San Antonio’s Fox News First at 7AM CST and San Antonio Living at 11AM CST tomorrow), is not only co-inventor of four of the company’s patents, with over two decades of industry management experience, he suffered a spinal injury himself in 1992 and is a tireless, dedicated researcher in the field. Additionally, David H. Koch Institute Professor at the Massachusetts Institute of Technology (MIT is another partner of the company), Robert S. Langer, widely renown in medicine, biotech, and tissue engineering science, is a key member of NVIV’s Scientific Advisory Board.
A one-year $4.50 price target for NVIV (closed February 17 at $2.18, $113M market cap), with pending human trials of potentially break-away technologies, essentially unopposed by any clear competitor in the same space, makes the opportunity look significantly undervalued. Potential to strike deeply into an estimated $10B annual global SCI market ($39B spent on larger care market associated with spinal cord injury in U.S. alone in 2011), means NVIV technologies could achieve revenues of more than a billion dollars by only capturing 10% of a market where clearly as many as half of all the approximately 2M SCI patients worldwide could benefit.
For more information on InVivo Therapeutics Corp., or to stay up to date on the latest news and information, please visit the company’s website at: www.InVivoTherapeutics.com
VistaGen Therapeutics (VSTA) Announces Engagement of MissionIR’s Investor Relations Services
VistaGen Therapeutics, Inc., a biotechnology company applying stem cell technology for drug rescue and cell therapy, has engaged MissionIR, a national investor relations consulting firm, to develop and implement a strategic investor relations campaign. Through a network of investor-oriented online websites and full suite of investor awareness services, MissionIR broadens the influence of publicly traded companies and enhances their ability to attract growth capital and improve shareholder value.
“VistaGen’s work with human stem cell technology is groundbreaking,” said Sherri Snyder, Director of Marketing at MissionIR. “The company’s versatile platform, Human Clinical Trials in a Test Tube™, provides clinically relevant predictions of potential heart toxicity of new drug candidates long before they are ever tested on humans. Guided by a management team with decades of experience, VistaGen’s stem cell technology can potentially save billions of dollars in the healthcare industry while recapturing prior R&D investment in once-promising new drug candidates.”
“We are pleased to bring MissionIR on board as our external investor relations partner,” said Shawn Singh, VistaGen’s Chief Executive Officer. “The crucial work our company is doing can fundamentally change the way medicine is developed. Paired with MissionIR’s global presence and sound investor relations programs, we can further grow our shareholder base and accelerate internal initiatives already in place to bring our stem cell technology platform to the forefront of drug development.”
VSTA Announces Engagement of MissionIR’s Investor Relations Services
VistaGen Therapeutics, Inc., a biotechnology company applying stem cell technology for drug rescue and cell therapy, has engaged MissionIR, a national investor relations consulting firm, to develop and implement a strategic investor relations campaign. Through a network of investor-oriented online websites and full suite of investor awareness services, MissionIR broadens the influence of publicly traded companies and enhances their ability to attract growth capital and improve shareholder value.
“VistaGen’s work with human stem cell technology is groundbreaking,” said Sherri Snyder, Director of Marketing at MissionIR. “The company’s versatile platform, Human Clinical Trials in a Test Tube™, provides clinically relevant predictions of potential heart toxicity of new drug candidates long before they are ever tested on humans. Guided by a management team with decades of experience, VistaGen’s stem cell technology can potentially save billions of dollars in the healthcare industry while recapturing prior R&D investment in once-promising new drug candidates.”
“We are pleased to bring MissionIR on board as our external investor relations partner,” said Shawn Singh, VistaGen’s Chief Executive Officer. “The crucial work our company is doing can fundamentally change the way medicine is developed. Paired with MissionIR’s global presence and sound investor relations programs, we can further grow our shareholder base and accelerate internal initiatives already in place to bring our stem cell technology platform to the forefront of drug development.”
GlobalWise Investments, Inc. (GWIV) Provides Introduction of Seasoned Management Team
Today before the opening bell, GlobalWise Investments, Inc. and its wholly owned subsidiary Intellinetics, Inc., a leading-edge technology company focused on the design, implementation and management of cloud-based Enterprise Content Management (“ECM”) systems in both the public and private sectors, provided an overview of the company’s new management team. The diverse roster of highly experienced professionals contribute a combined total of more than 150 years in ECM industry experience.
William J. “BJ” Santiago, President and CEO. BJ has more than 20 years of senior executive-level management experience with an emphasis in sales, operations and M&A activities in the public and private sectors. During his previous tenure at Lexmark, BJ was hand selected in 2008 by the Lexmark CEO to launch and lead all operations for the newly formed Content Management Sales Practices for North America, which was using the Intellinetics platform. Through this business venture, Intellinetics recognized his ability as an ECM industry thought leader. From here, he became a natural catalyst for Intellinetics’ business development and strategy. BJ also served eight years as a United States Army Infantry Officer and is a veteran of Operation Desert Storm.
Matthew Chretien, EVP and Chief Technology Officer. Matthew is a co-founder of Intellinetics and a strategic entrepreneur backed by more than 20 years of experience in technology sales, consulting and software product life cycle management within the aerospace, public safety, government and select commercial markets. After graduating from The Ohio State University with an engineering degree in 1990, he spent two years in the Fisher College of Business Doctoral Program at Ohio State in computer science to work on his Ph.D. During this period, Matthew discovered his research would be far too narrow to satisfy his interests and ultimately co-founded Intellinetics in 1994.
Michael Chretien, VP and Corporate Counsel. Michael is a co-founder of Intellinetics. After graduating from the University of Massachusetts with a Bachelor of Arts in economics in 1961, he joined the United States Marine Corps and retired in 1965 as a 1st Lieutenant. Michael continued to serve his country for 26 years in law enforcement and foreign counter intelligence. After retirement from government service, he continued his career in the law enforcement field by studying for his Juris Doctorate and was awarded a law degree from Capital University Law School in 1991. Michael’s next move was founding Intellinetics with his son Matthew using his law enforcement background as a client resource to consult and assist with document storage and various other IT-related solutions.
Thomas D. Moss, Chief Software Engineer. Tom is a co-founder of Intellinetics and director of the company’s software research and development efforts. He boasts 20 years of expertise in database application design and document imaging software technologies, and has earned both a mathematics degree and a computer science degree at the University of Wisconsin.
Michael A. Beck, Director of Operations. Mike brings to Intellinetics 17 years of IT experience, including IT management, hands on technical experience, departmental management, staff development, budget development and management, network design, large-scale project management, creation of a new IT telecommunications department, contract negotiations, vendor management and technology migrations. Mike has proven his ability to consistently bring projects in on time and within budget.
Neil C. Campbell, Director of Software Products Group. Neil has 16 years of experience in the IT field with an emphasis in infrastructure design, software architecture and productivity improvement solutions. Neil spent 11 years at Abbott Laboratories with focus on manufacturing IT operations and warehouse management systems before he joined Intellinetics as a project manager in fall of 2006. Neil was promoted to Director of Software products in 2008, where he currently contributes visionary leadership, thoughtful interpretation, diagnosis and resolution to complex business issues facing companies today and in the future. Neil holds a bachelor’s degree from The Ohio University and industry certifications from Microsoft, Cisco, Extreme Networks, HP, Dell, Marathon Technologies and IBM.
Jim Perry, Director of Business Development. Jim has more than 15 years of executive sales and marketing experience providing Electronic Content Management (ECM), workflow and advanced data capture solutions to the healthcare, government and insurance markets. Jim previously served as a Senior Account Executive for ImageSoft, Inc. where he was responsible for developing and selling ECM solutions to the healthcare, government, manufacturing and insurance markets. Jim was personally responsible for innovating and developing a marketing plan for the healthcare vertical market that resulted in ImageSoft being recognized in 2008 as No. 1 of more than 200 reseller integrators of OnBase ECM Software in the United States.
Robert Simmons, Director of Business Development. Robert’s experience in the print and imaging industry spans 15 years. He most recently served as the Director of Enterprise Solution Architecture for Samsung Electronics. Robert has been responsible for creating programs and services that analyze vertical market requirements for document and output solutions, which have resulted in millions of dollars in cost savings and efficiency gains. He has specialized in developing programs and solutions for healthcare, government and education customers in North America. Robert holds a bachelor’s degree in psychology from Lee University and an MBA from the University of Phoenix.
Randy Love, Director of Business Development. Over the past 10 years of his 25-year IT career, Randy’s efforts have been focused on the ECM market. Most recently he worked 4 years as the VP of Sales and Business Development at an Ohio based ECM provider counting a number of complex, multi-million dollar imaging solutions to his team’s credit. He also spent 4 years as a Government Industry Manager at Hyland Software where he was credited with assisting partners on numerous high profile public sector projects as well as leading direct efforts on a statewide SAP integration deal. Prior to focusing on the ECM industry, Randy spent five years marketing mobile data software solutions to criminal justice agencies and 10 years in the commercial sector with a national systems integration firm. Early in his career, Randy worked as a Systems Engineer and Programmer Analyst, which has transcended to the technical aptitude he brings to his current position. He is a Certified Document Imaging Architect (CDIA+), AIIM ECM Practitioner and computer science graduate with a Bachelor of Science from Youngstown State University.
Bob Peterson, Director of Business Development. Bob has over 20 years of senior management experience with an emphasis in channel sales, business development and marketing. Bob has most recently been the Director of Healthcare for Seneca, a market leader with a wide range of products, engineering and software services. At Intellinetics, Bob will continue to partner with Seneca, working together to jointly develop various strategic partners. Bob was a VP of Sales and Marketing at Optio Software, a leader in Electronic Document Management and Information optimization used in healthcare, government and commercial markets. Bob’s team developed and successfully marketed an Electronic Document Management solution that successfully lowered cost and increased efficiency for hospitals and helped meet HIPPA requirements, JACOH standards and enhanced Electronic Medical Record implementations.
GWIV Provides Introduction of Seasoned Management Team
Today before the opening bell, GlobalWise Investments, Inc. and its wholly owned subsidiary Intellinetics, Inc., a leading-edge technology company focused on the design, implementation and management of cloud-based Enterprise Content Management (“ECM”) systems in both the public and private sectors, provided an overview of the company’s new management team. The diverse roster of highly experienced professionals contribute a combined total of more than 150 years in ECM industry experience.
William J. “BJ” Santiago, President and CEO. BJ has more than 20 years of senior executive-level management experience with an emphasis in sales, operations and M&A activities in the public and private sectors. During his previous tenure at Lexmark, BJ was hand selected in 2008 by the Lexmark CEO to launch and lead all operations for the newly formed Content Management Sales Practices for North America, which was using the Intellinetics platform. Through this business venture, Intellinetics recognized his ability as an ECM industry thought leader. From here, he became a natural catalyst for Intellinetics’ business development and strategy. BJ also served eight years as a United States Army Infantry Officer and is a veteran of Operation Desert Storm.
Matthew Chretien, EVP and Chief Technology Officer. Matthew is a co-founder of Intellinetics and a strategic entrepreneur backed by more than 20 years of experience in technology sales, consulting and software product life cycle management within the aerospace, public safety, government and select commercial markets. After graduating from The Ohio State University with an engineering degree in 1990, he spent two years in the Fisher College of Business Doctoral Program at Ohio State in computer science to work on his Ph.D. During this period, Matthew discovered his research would be far too narrow to satisfy his interests and ultimately co-founded Intellinetics in 1994.
Michael Chretien, VP and Corporate Counsel. Michael is a co-founder of Intellinetics. After graduating from the University of Massachusetts with a Bachelor of Arts in economics in 1961, he joined the United States Marine Corps and retired in 1965 as a 1st Lieutenant. Michael continued to serve his country for 26 years in law enforcement and foreign counter intelligence. After retirement from government service, he continued his career in the law enforcement field by studying for his Juris Doctorate and was awarded a law degree from Capital University Law School in 1991. Michael’s next move was founding Intellinetics with his son Matthew using his law enforcement background as a client resource to consult and assist with document storage and various other IT-related solutions.
Thomas D. Moss, Chief Software Engineer. Tom is a co-founder of Intellinetics and director of the company’s software research and development efforts. He boasts 20 years of expertise in database application design and document imaging software technologies, and has earned both a mathematics degree and a computer science degree at the University of Wisconsin.
Michael A. Beck, Director of Operations. Mike brings to Intellinetics 17 years of IT experience, including IT management, hands on technical experience, departmental management, staff development, budget development and management, network design, large-scale project management, creation of a new IT telecommunications department, contract negotiations, vendor management and technology migrations. Mike has proven his ability to consistently bring projects in on time and within budget.
Neil C. Campbell, Director of Software Products Group. Neil has 16 years of experience in the IT field with an emphasis in infrastructure design, software architecture and productivity improvement solutions. Neil spent 11 years at Abbott Laboratories with focus on manufacturing IT operations and warehouse management systems before he joined Intellinetics as a project manager in fall of 2006. Neil was promoted to Director of Software products in 2008, where he currently contributes visionary leadership, thoughtful interpretation, diagnosis and resolution to complex business issues facing companies today and in the future. Neil holds a bachelor’s degree from The Ohio University and industry certifications from Microsoft, Cisco, Extreme Networks, HP, Dell, Marathon Technologies and IBM.
Jim Perry, Director of Business Development. Jim has more than 15 years of executive sales and marketing experience providing Electronic Content Management (ECM), workflow and advanced data capture solutions to the healthcare, government and insurance markets. Jim previously served as a Senior Account Executive for ImageSoft, Inc. where he was responsible for developing and selling ECM solutions to the healthcare, government, manufacturing and insurance markets. Jim was personally responsible for innovating and developing a marketing plan for the healthcare vertical market that resulted in ImageSoft being recognized in 2008 as No. 1 of more than 200 reseller integrators of OnBase ECM Software in the United States.
Robert Simmons, Director of Business Development. Robert’s experience in the print and imaging industry spans 15 years. He most recently served as the Director of Enterprise Solution Architecture for Samsung Electronics. Robert has been responsible for creating programs and services that analyze vertical market requirements for document and output solutions, which have resulted in millions of dollars in cost savings and efficiency gains. He has specialized in developing programs and solutions for healthcare, government and education customers in North America. Robert holds a bachelor’s degree in psychology from Lee University and an MBA from the University of Phoenix.
Randy Love, Director of Business Development. Over the past 10 years of his 25-year IT career, Randy’s efforts have been focused on the ECM market. Most recently he worked 4 years as the VP of Sales and Business Development at an Ohio based ECM provider counting a number of complex, multi-million dollar imaging solutions to his team’s credit. He also spent 4 years as a Government Industry Manager at Hyland Software where he was credited with assisting partners on numerous high profile public sector projects as well as leading direct efforts on a statewide SAP integration deal. Prior to focusing on the ECM industry, Randy spent five years marketing mobile data software solutions to criminal justice agencies and 10 years in the commercial sector with a national systems integration firm. Early in his career, Randy worked as a Systems Engineer and Programmer Analyst, which has transcended to the technical aptitude he brings to his current position. He is a Certified Document Imaging Architect (CDIA+), AIIM ECM Practitioner and computer science graduate with a Bachelor of Science from Youngstown State University.
Bob Peterson, Director of Business Development. Bob has over 20 years of senior management experience with an emphasis in channel sales, business development and marketing. Bob has most recently been the Director of Healthcare for Seneca, a market leader with a wide range of products, engineering and software services. At Intellinetics, Bob will continue to partner with Seneca, working together to jointly develop various strategic partners. Bob was a VP of Sales and Marketing at Optio Software, a leader in Electronic Document Management and Information optimization used in healthcare, government and commercial markets. Bob’s team developed and successfully marketed an Electronic Document Management solution that successfully lowered cost and increased efficiency for hospitals and helped meet HIPPA requirements, JACOH standards and enhanced Electronic Medical Record implementations.
Noted - thank you!
CUI Global (CUI) Begins Trade on NASDAQ Exchange, Announces $10 Million Equity Raising
CUI Global Inc., a platform company engaged in the acquisition, development, and commercialization of innovative technologies, today announced it is now listed and trading on the NASDAQ exchange and will preside over the NASDAQ closing bell ceremonies today at 4 p.m. EST.
In conjunction with the listing, the company also announced it has raised equity of $10 million with assistance of its US Investment Banker, Merriman Capital Inc. (MERR) and its London advisor, Prosdocimi Ltd.
CUI Global said it will use the proceeds for working capital to pay down and retire certain corporate debt as well as rapidly bring to market its new Vergence™, Novum ™, and Solus ™ Technologies.
“This equity raise and the up-listing represent significant milestones for CUI Global and its shareholders,” CUI Global president and CEO William Clough stated in the press release. “These funds will enable us to retire yet more debt and to dramatically speed up the development and commercialization of our leading-edge natural gas and electronics technologies.”
Clough said listing on a national exchange enables CUI Global to broaden its shareholder base and increase visibility for company achievements. The listing also reflects collaborative efforts to advance the company in the marketplace.
“With the support of our shareholders, the assistance of Merriman Capital and Dorian Prosdocimi in Europe, and the tireless efforts of our entire team, we have successfully taken this company to the next level of its development; thus, continuing our strategy of retiring debt, increasing revenues, and enhancing shareholder value,” Clough stated.
For more information visit www.cui.com
Nanosphere, Inc. (NSPH) Reports Q4 and FY2011 Results
Nanosphere, Inc. yesterday announced its financial results for the fourth quarter as well as the full year results of 2011. Revenue and sales were up over the previous year, while operating expenses went down, with an overall reduction in net loss.
Nanosphere manufactures and markets the Verigene System, an advanced molecular diagnostics platform designed for direct genomic and ultra-sensitive protein detection. The company boasts that the system is a cost-effective and easy way to test highly sensitive genomes and proteins.
Nanosphere’s revenues were up by $.5 million for the year, from $2 million to $2.5, while product sales rose from $1.4 million to $2.4 million. Operating expenses fell to $38 million from $43.4 million in 2010, in part by a reduction in legal fees and settlements due to a patent dispute that was settled in 2010.
Net loss during 2011 was reduced to $35.4 million versus $40.6 million during 2010. Net loss in Q4 was reported at $8.6 million, compared to the previous year’s net loss of $7.4 million. Cash flow during Q3 and Q4 2011 was negative $7.6 million, and cash at December 31, 2011, was $39.3 million.
William Moffitt, Nanosphere’s president and CEO, said, “We shipped 30 systems to new customers during the fourth quarter demonstrating an inflection point has been reached in our business. The investments we have made in menu expansion, particularly in the microbiology market segment, have generated significant customer interest and demand.”
L & L Energy, Inc. (LLEN) Concludes Inspection Trip to Chinese Coal Mine
L & L Energy announced the conclusion of a management visit to a recently acquired coal mine located in Guizhou Province, China. The visit was led by top officials of the company and also included due diligence inspections on other prospective acquisition opportunities.
In January 2012, L & L Energy announced the acquisition of a 51% interest in the Weishe coal mine for total consideration of $16.2 million. The company issued three million shares of common stock to Union Energy Co. in the deal.
The Weishe coal mine has 19 million tons of coal reserves located in a 1.8 square kilometer section of the property. The mine has a design capacity of 450,000 tons of coal per year.
The visit to the Weishe coal mine was led by Ed Moy and Dr. Syd Pend. Mr. Moy is a Vice President at L & L Energy and Dr. Pend is a member of the company’s board of directors. The two officials reported that the mine was designed with high safety standards and was impressed by the strength of the mine’s management team.
Mr. Moy and Dr. Pend also visited two other coal mines in the area owned by Union Energy Co. and plan to make a future due diligence trip to the facilities.
For more information on the company, go to www.lnlinternational.com
Threshold Pharmaceuticals, Inc. (THLD) Names Dr. Tillman Pearce as Chief Medical Officer
Threshold Pharmaceuticals, a biotechnology company, announced today that it has appointed Tillman Pearce, M.D., as its chief medical officer. Dr. Pearce will oversee development of the company’s TH-302, a clinical stage hypoxia-targeted cancer therapeutic currently being evaluated in a variety of cancers. TH-302 is presently undergoing a phase 3 trial in soft tissue sarcoma patients and a phase 2b trial in pancreatic cancer patients.
Dr. Pearce has expertise in oncology drug development – both from the perspectives of large pharmaceutical companies and smaller entrepreneurial biotech companies. His almost two decades of international drug development experience will be valuable to Threshold as the company builds its new partnership with Merck KGaA.
Dr. Pearce’s professional history includes serving as director of oncology clinical research for Sandoz/Novartis, medical director at Sanofi-Synthelabo’s Oncology Business Unit, and founder and director of PDL BioPharma France. Dr. Pearce most recently served as chief medical officer of KaloBios Pharmaceuticals.
Threshold Pharmaceuticals focuses on discovering and developing drugs that target tumor hypoxia, a low oxygen condition found in the microenvironments of most solid tumors and the bone marrows of some hematologic malignancies. This approach offers wide-ranging potential for treating a variety of cancers. By selectively targeting tumor cells, the company is building a pipeline of promising drugs that will more effectively treat cancers with less toxicity to healthy tissues.
For further information about the company, visit www.thresholdpharm.com
Updated GWIV 8-Page Investor Summary
http://gwiv.missionir.com/ir
Unemployment Filings Fall to Nearly 4-Year Low
Unemployment filings unexpectedly fell to a four-year low last week, indicating that the labor market could be recovering. Other data from this month show solid expansion in factory activity in the Mid-Atlantic area. In January, builders broke more ground on new residential projects, offering more evidence of a sustained momentum in the economy.
The reports are the latest in a series of fairly upbeat data. Some think that the positive numbers could prompt economists to further temper expectations of a sharp moderation in growth in the first quarter. Similarly, economists have dialed down their expectations for another round of bond-buying or quantitative easing by the Federal Reserve.
“The numbers add to the belief that the economy is shifting gears. There is just no number that is giving us a whole lot of trouble, except for consumer spending,” said Joel Naroff, chief economist at Naroff Economic Advisors in Holland, Pennsylvania.
The Labor Department stated that initial claims for state unemployment benefits dropped 13,000 to a seasonally adjusted 348,000, the lowest level since March 2008. Economists polled by Reuters had forecast claims rising to 365,000. The four-week average of new claims, seen as a better measure of labor market trends, was the lowest since April 2008.
Regarding activity at factories, factories in the region covering eastern Pennsylvania, southern New Jersey and Delaware generally increased hours for existing employees, which usually bodes well for wage growth.
“We are not seeing much indication that growth has slowed from the fourth quarter of 2011 to the first quarter of 2012,” said Gus Faucher, senior economist at PNC Financial Services in Pittsburgh, Pennsylvania.
The Commerce Department reported that housing starts rose 1.5 percent to an annual rate of 699,000 units last month. Economists had predicted a pace of about 675,000 units. Multi-unit buildings boosted the starts, reflecting growing demand for rental apartments as Americans move away from homeownership. Permits for future home construction rose 0.7 percent to a 676,000-unit pace in January. Home building is expected to add to economic growth this year for the first time since 2005.
AdCare Health Systems, Inc. (ADK) Continues Fast Growth
The recent positive assessment of AdCare Health Systems by Stonegate Securities was based upon the strength of AdCare’s unique approach to a growing but highly fragmented market. AdCare is an Ohio-based healthcare services provider that owns, operates, and manages skilled nursing homes, assisted living facilities, and retirement communities in several states, largely in the southeast. The company has recognized and is aggressively addressing a major need in the living facilities industry, which today consists largely of independent family owned operations. These facilities are generally oriented toward low-margin long-term care, and also have inherent and costly operational inefficiencies.
AdCare’s successful approach has been to identify and acquire such operations, focusing on certain key parameters, such as targeting locations in states with relatively healthy economies. AdCare then applies a customized improvement program, carefully tailored to each facility’s needs, effectively moving it into a higher-margin acute-care Medicare-based model, as well as introducing a variety of more efficient operational standards and procedures.
The result is a gradual but steadily improving financial picture for both the individual facility and for AdCare. The company’s Medicare census has, for example, increased by over 37% at acquired facilities, and AdCare has also been able to offset recent Medicare cuts. AdCare’s seasoned management team has substantial senior living, healthcare, and real estate industry experience, and is itself incentivized to continue to grow the business through their combined ownership of approximately 25.6% of the common AdCare stock.
AdCare’s revenues continue to show steady growth, as they have for the past several years. With the recent acquisition of a number of skilled nursing centers they expect to close in the first quarter of 2012, AdCare expects its annualized revenue run-rate to exceed $355 million, which would represent an increase of 570% over revenues in 2010.
For additional information, visit the company’s website at www.AdCareHealth.com
Ambient Corp. (AMBT) Reports Record Revenues in 2011
Ambient Corp. is a leading provider of smart grid communications platforms and applications to utilities. The company designs, develops, and sells Ambient Smart Grid products and services which include communications nodes, a network management system, AmbientNMS integrated applications, and maintenance and consulting services.
The company today reported financial results for the year ended December 31, 2011. Total revenue for 2011 was $62.3 million, a 206% increase from $20.4 million in 2010. Net income came in at $4.8 million, or 28 cents per diluted share, compared to a net loss of 21 cents a share last year. Ambient’s gross margin increased somewhat too, from 41% last year to 43% in 2011. Finally, its cash position increased to $18 million at year-end from $7 million at the end of 2010.
As can be seen from the numbers, Ambient experienced significant growth last year. It also achieved many key operational milestones. For example at the end of 2011, the company had over 75,000 communications nodes deployed in the field communicating with over 700,000 smart grid end devices. The company is partnered with leading companies in the “smart” meter sector like Itron and Badger Meter and is also partnered with leading utility, Duke Energy.
Interest in Ambient’s communications platform continues to grow and the company is pursuing projects with other potential customers. Its president and CEO, John J. Joyce, said, “On the foundation of a strong balance sheet, driven by field-proven technology…we believe we are well positioned to execute on a primary objective for 2012 – the diversification of our customer base.”
For additional information about Ambient, please visit its website at www.ambientcorp.com
Paramount Gold and Silver Corp. (PZG) New Assay Results Expand San Miguel Gold Project Core Zone, New High-Grade Zone Discovered
Today, Paramount Gold and Silver, strongly positioned in North American precious metals development via their 100%-owned Sleeper (Nevada) and San Miguel (Mexico) projects (in addition to their other sites in Nevada at Spring Valley, Reese River, and the 100%-owned Mill Creek Gold Project), reported high-grade assay results from new drilling during exploration of a 1km gap in the San Miguel’s Veronica-Santa Clara mega structure.
Two drill holes (LU-12-026 and -027), targeting right angle vectors for true width intercepts, discovered a new high-grade gold zone on the La Union deposit’s southern edge, extending into the untested gap. The 027 hole, 8.65m intercept yielded a 13.02 g/t Au, 19.27 g/t Ag return and is nestled in a larger mineralization area containing a 79m wide zone (observed true width of no less than 60m) of huge veins/stockworks grading, on average 3.70 g/t Au and 17.34 g/t Ag.
The La Union also has great news and may well prove to be the highest grade deposit in the entire Palmarejo District, as another hole, 025, in the center of the La Union intersected 7.75m at 29.51 g/t Au and 19.11 g/t Ag, including 1.35m at 156.83 g/t Au and 77.82 g/t Ag. These results confirm the exceptional grades of the La Union core and should lead to a nice increase in the size of the defined core area.
Mine Development Associates out of Reno should be bringing in a new resource estimate by the second quarter covering the entire San Miguel project and this estimate will contain extant results from 2011-2012 drilling. This report will then be used for a preliminary economic assessment slated for later in 2012 that will evaluate projections for a preliminary feasibility study, resulting in a reserve report. Exploration will also continue on the massive property and a series of potential targets are scheduled for pursuit according to arrived at priorities.
CEO of PZG, Christopher Crupi, offered some choice words on the excellent assay results, underscoring the importance of the new high-grade zone discovered as a potential “game-changer” for the San Miguel Project. Crupi then delineated the validity of his statement:
First – this is a major step towards proving the some 4.35 mile Veronica-Santa Clara corridor has a continuous mineralization structure, for which the deposits are salient nodes and that the roughly 1.7 miles of undrilled gaps throughout the corridor are much more exciting as a result.
Second – expanded width potential evidenced by hole 027 results indicate potential for an even more lucrative open pit operation.
Third – Crupi indicated that the discoveries of gold-rich zones at depth below the already identified silver mineralization was a very strong indicator of the potential at San Miguel.
Confidence is high at PZG and there are numerous untested targets to be looked at as extension to known deposits, the Mexican properties are looking great and the company also has its Nevada positions. Exploration at San Miguel is being carried out under PZG’s VP of Exploration, Glen van Treek, by Gold de Mexico S.A de C.V personnel. Bill Threlkeld is serving the Qualified Person role as per NI 43-101 definitions and both men have approved today’s report.
Paramount is clearly excited and is rapidly pursuing quality control/assurance protocols as per assay batching standards. Secondary lab work is being conducted for cross-checking analysis at an external lab across 10% of samples and things are really shaping up at San Miguel to make PZG’s operations in Mexico a very sturdy second leg to the rapidly emerging Sleeper Project in NV. The company is on very solid footing with this report and investors will be keen to hear additional reports out of PZG as activity at San Miguel heats up.
For more information on the report, or to stay up to date on the latest developments at Paramount Gold and Silver Corp., please visit the company’s website at: www.ParamountGold.com
NeoGenomics, Inc. (NGNM) Posts Financial Strength in Q4, FY 2011
NeoGenomics, a high-complexity CLIA–certified clinical laboratory specializing in cancer genetics diagnostic testing, today reported its results for the fourth quarter and full year 2011.
“We are very pleased with our Quarter 4 results. For the third quarter in a row we posted the largest year-over-year and sequential quarterly increases in revenue in our corporate history, and our revenue growth rate continued to accelerate throughout the quarter,” Douglas M. VanOort, the company’s chairman and CEO stated in the press release. “Our sales teams were also more productive, as we achieved excellent revenue growth while keeping sales and marketing costs essentially unchanged from Quarter 4 last year. The improved operating leverage from our SG&A expenses allowed us to return to profitability.”
The company posted fourth-quarter revenue at $12.9 million, up 47 percent compared to fourth-quarter revenue of $8.8 million reported for 2010.
Net income for the 2011 fourth quarter was $152,000, or $0.00 per share, compared to a net loss of $377,000 or ($0.01) per share, reported for the fourth quarter of last year. Adjusted EBITDA increased by more than $1.0 million to $1.1 million from $29,000 last year.
For the full year 2011, NeoGenomics reported revenue of $43.5 million, a 27 percent increase over 2010 revenue of $34.4 million.
The company reported a 2011 net loss of $1.2 million or ($0.03) per share, compared to a net loss of $3.3 million or ($0.09) per share in 2010. Adjusted EBITDA for the year increased by $2.7 million to $2.1 million from a loss of $566,000 reported in 2010.
“Our performance improved steadily throughout the year with revenue growth rates and gross margin increasing sequentially in each of the four quarters of 2011,” VanOort continued. “Although average revenue per test declined in 2011, we were able to offset most of that impact with increases in productivity. We also maintained tight cost control throughout 2011. SG&A expense for the full year increased only slightly from 2010, and nearly half of the increase was for normal bad debt expense associated with the strong increase in revenue.”
The Company expects revenue between $54 million – $59 million and net income of $0.02 – $0.04 per share for 2012. For the fiscal first quarter, NeoGenomics said it expects revenue of $13.5 million – $14.0 million and net income of $0.00 to $0.01 per share.
“We believe we are well positioned for continued success. Our current sales pipeline is healthy, and we plan to launch several new sales and marketing initiatives to expand our strategic partnerships with large clients. We also expect a stable reimbursement environment this year, which should allow us to make further improvements in gross margin and profitability. In addition, we plan to significantly expand our molecular and immunohistochemistry test menus, launch the second test under our agreement with Abbott Molecular, and make important investments to begin developing the technology and tests we licensed from Health Discovery Corp,” VanOort stated.
For more information visit www.neogenomics.com
SMTC Inc. (SMTX) is “One to Watch”
SMTC is a global Electronics Manufacturing Services (EMS) provider focused on supporting the growth of its customers through competition, improved margins, and increased market share.
By offering a full range of services, the company’s solutions are applicable to a wide customer base that includes industrial, computing, communications, consumer, medical, and renewable energy markets. SMTC’s industry experience spans every base of leading-edge manufacturing, covering the entire life cycle of electric products, from development and introduction to growth and maturity and end-of-life phases.
Customer loyalty and retention are a must in this competitive industry, and it’s worth noting that most of the company’s customers have stuck around for more than seven years, and some for more than fifteen. Also notable, nine of its Top 10 customers are No. 1 in their respective markets.
After coming out of the third quarter, the company’s expertise and market reach seem to be paying off.
Per guidance issued in October 2011, the company is expected to announce improved financial performance for the fourth quarter based on new customers, cost reduction initiatives, and its recent acquisition of ZF Array Technology Inc. in September 2011.
SMTC significantly raised its fourth-quarter guidance to $4.0 million EBITDA on revenues of $69 million compared to previous guidance of $3.0 million.
“As recently appointed CEOs, we are cautious about providing new guidance, but our increased forecast reflects the strengthening of the business. In order to meet higher Q4 orders, we added to labor and increased working capital in late Q3. However, we continue to expect to generate positive operating cash flow for the year, and to generate strong free cash flow in 2012,” Alex Walker, co-CEO stated in the press release.
SMTC is slated to announce its fourth-quarter and full-year results March 7.
For more information visit www.smtc.com
Merge Healthcare Inc. (MRGE) iConnect Medical Imaging Data Platform Further Embraced by Massive Chicago Multi-Specialty Physician DuPage Medical Group
Today, Merge Healthcare, the industry veteran with two decades of experience providing healthcare facilities with the cutting-edge in medical enterprise imaging and innovative interoperability solutions for radiology, cardiology, orthopedics, and eye care, announced that the Merge iConnect® Access and the Merge Eye Care suite have been elected by DuPage Medical Group for addition to their solution set.
DuPage is one of Chicago’s biggest multi-specialty independent physician groups and has some 45 locations in the western suburbs, with a staff of some 330 physicians. The massive challenge of delivering images in a timely manner out to the referring physician base, and between staff throughout the operation, is greatly improved with iConnect Access which creates a throughput environment to radically simplify and streamline the process of exchanging critical imaging data.
Via Merge’s integrated suite of software solutions, DuPage Medical Group, which serves one-third of all DuPage County, will enhance their existing platform to simultaneously both eliminate disparate data silos and crystallize a truly seamless imaging environment that spans the entire enterprise. Merge iConnect Access lets physicians throughout the entire network of persons connect seamlessly via the internet using any approved intelligent networked device, making it easy for physicians to rapidly confer/deliberate regarding imaging data irrespective of image type (radiology, cardiology, etc.) thanks to a multi-specialty viewer. No additional software downloads required and seamless integration of devices via a web-based solution.
CEO of the DuPage Medical Group, Dennis Fine, extolled the benefits of Merge iConnect and explained how they used it to connect silos of imaging data to image-enable their EMR so physicians could rapidly deal with images generated from any specialty, all within a networked environment. This methodology allows for huge collaboration improvements and lets radiologists speed up their workflow dramatically, something Fine is confident will enhance care delivery.
CEO of MRGE, Jeff Surges, underscored how such implementation of the company’s technology to successfully execute on an “enterprise-wide imaging strategy” helps to increase the density of the very foundations upon which healthcare is provided, improving how care is delivered to the end user. Surges’ comments were not lost on industry analysts when he detailed this as a perfect case history and example, saying that the large and complex DuPage Medical Group now has an end-to-end solution that integrates with their Epic EMR, giving DuPage radiologists unprecedented workflow, ease of use, and access when it comes to handling patient medical records.
This is vital to overall success in any given situation for radiologists because time is a huge factor and it is difficult as it is to handle the nuanced, unique requirements of providing patient care. Access to data and the ability to exchange that data rapidly within a unified environment that is intuitive cannot be overstated in its importance.
Merge Eye Care Solutions provide a comprehensive backdrop for ophthalmic image and informatics, granting eye care specialists a huge boost to process efficiencies and substantially improving the results of their effort. The portable Merge EyeScan™ imaging device is part of this series and has an extremely modular design for both anterior and posterior segments, is easy to use, yet provides great diagnostics. Other offerings like the Merge Eye Station™ (capture software and interface for extant fundus cameras) and Merge Eye Care PACS™ (web-based image management) complete the package with comprehensive tools to make working with critical data even easier.
For more information on the announcement, or on Merge Healthcare, please visit the company’s website at: www.Merge.com
China Sunergy Co. (CSUN) Executes Sales Contract with Bull PowerTech
China Sunergy Co., Ltd., a specialized solar cell and module manufacturer, recently announced that it has executed a 50-MW sales contract with Bull PowerTech GmbH. The contract concerns projects in Europe; the shipment is expected to be fully completed by the end of 2012.
Bull PowerTech is a renewable energy company focused on photovoltaics. A 100% subsidiary of Bull Holding AG, the company plans and installs large solar parks and works with leading suppliers to create turn-key solar kits with individually coordinated components. Bull PowerTech has built up a high profile and stable customer base in the European Market.
Manuel Thaler, Bull Holding COO, remarked, “We are highly satisfied with China Sunergy’s product quality, technologies and services after visiting their manufacturing plants. We only work with first class manufacturers with the best technologies and under the strictest quality controls. By partnering with China Sunergy, we are confident that we are able to meet the needs and requirements of our demanding clients.”
Stephen Cai, CEO of China Sunergy, added, “We are happy to start the year with this high volume contract. Bull PowerTech is just the type of reputable and creditworthy customer that we most like to work with in the PV industry. We value this relationship and will seek more opportunities to cooperate with Bull PowerTech to expand our market share in the future.”
KongZhong Corp. (KONG) Acquires Smartphone Mobile Game Engine Company Noumena
Located in Beijing, China, KongZhong is a leading provider of digital entertainment services for consumers in China. Today, the young company took a major step towards prominence with the announcement it has entered into definitive agreements to acquire 100% of the equity interest in Noumena Innovations (BVI) Ltd and certain assets from a related party.
The total consideration for the acquisition is $15 million, which is payable over three years from the closing of the transactions, and 40.0 million of the company’s ordinary shares, which are subject to a three year lock up period.
Noumena is the developer of Handymo, a cross-platform smartphone mobile game engine. The Handymo game engine, using its proprietary JavaScript-based development environment, supports all major smartphone mobile game platforms, including iOS, Android, and HTML5, allowing for more rapid and cost-effective development of smartphone games, including 3D mobile massively multiplayer online (“MMO”) games.
The company intends to integrate the Noumena team into its existing mobile game development team of more than 100 employees in order to create new smartphone mobile games that will take advantage of the Handymo game engine technologies. The company believes this new generation of smartphone mobile games will enable it to leverage its existing mobile game distribution channels in China and capture market share in the nascent PRC smartphone mobile games market, separate from the company’s existing feature phone mobile game business.
Currently, KongZhong is trading in the $4.48 range. To learn more about the company as a whole, visit their corporate website at http://ir.kongzhong.com
GlobalWise Investments (GWIV) is “One to Watch”
GlobalWise Investments, via wholly-owned subsidiary Intellinetics, Inc., is a leading-edge technology company focused on Enterprise Content Management (ECM) solutions for the digital age. The ECM industry continues to grow rapidly as a result of unrestricted proliferation of digital content within today’s business environment. Leveraging its proprietary cloud-based computing software, GlobalWise is poised to capture a significant market share of this burgeoning industry.
GlobalWise’s ECM service is delivered to customers via five unique delivery models which cover the spectrum of business needs: Cloud/Saas (Software as a Service), Hardware Vendor Integrated Service, Software Vendor Integrated Service, Premise (Client-Server), Hybrid (Premise & Cloud/Saas).This diversity gives advanced security & privacy features with an on-demand structure needed for large Tier 3 and Tier 4 businesses that are currently underserved by the market.
The Intellinetics platform defines a new industry benchmark and game-changing approach by combining advanced virtualization & automated content management with an open and service-oriented architecture using web services. The company provides strategies, tactics, and technologies used to manage paper and digital assets from capture to long-term archive, without the need for manual processes conducted by a full time employee.
GlobalWise’s management boasts a combined total of over 60 years in ECM leadership and industry experience. The ECM industry is expected to exceed $5.1 billion by 2013 with Gartner predicting a compound annual growth rate of 9.5%. IBM Market Insights predicts adoption of cloud computing to grow by 26% CAGR between 2010 through 2013. Leveraging management and key department heads, Intellinetics has a strong foundation from which to capture significant market share within the lucrative $149 billion Business Software & Services industry.
Key Investment Highlights
Cutting-Edge Solutions that Increase Productivity and Cut Costs
ECM Industry Expected to Exceed $5.7 Billion by 2014 with 10.1% CAGR
Industry’s First ECM App Store to Drive Mobility Usage and Capability
Market Leader with Proprietary Software and Experienced Management
Quantum Fuel Technologies Worldwide, Inc. (QTWW) Releases New High-Capacity Natural Gas Storage Tank for Commercial Fleets
Quantum Fuel Technologies Worldwide announced the release of its new composite compressed natural gas (CNG) tank. Use of commercial natural gas fleets, including refuse truck applications, is an expanding trend that is expected to accelerate. Quantum’s new 400 Series CNG storage tank was designed utilizing customer feedback, making installation and service easier and distinguishing Quantum’s composite tanks from those marketed by competing companies. The 400 Series has a Diesel Gallon Equivalency (DGE) of 26 gallons, and Quantum’s composite tanks are the lightest in the industry – increasing available payload by requiring less structure for mounting support.
An incentive has been proposed by President Obama to offer a credit equivalent of 50 percent of the extra cost of purchasing natural gas-powered trucks for those buying them. Incentives like this make converting to natural gas fuel even more attractive – further inducing buyers to consider fuel that is clean burning, inexpensive, and made in the United States. Natural gas-powered trucks also offer short payback and high return on investment.
With around 140,000 refuse trucks on the road in the U.S., it is reported that a 1,300 percent increase in use of natural gas-powered refuse trucks has occurred since the 1990s. The country’s largest refuse companies – Waste Management and Republic Services – are converting significant numbers of their fleets to CNG. Waste Management had 17 CNG refueling stations as of August 2011 and another 30 in the works. Republic Services had around 500 CNG-powered refuse trucks in operation as of August 2011, and the company aims to have 800 CNG trucks on the road by the end of 2012.
Quantum Fuel Systems Technologies Worldwide is a global leader in developing and producing advanced propulsion systems, energy storage technologies, and alternative fuel vehicles. A fully integrated alternative energy company, Quantum’s portfolio of technologies includes electronic controls, hybrid electric drive systems, natural gas and hydrogen storage and metering systems, and alternative fuel technologies. Quantum’s subsidiary, Schneider Power Inc., and its affiliate Asola Advanced and Automotive Solar Systems GmbH add to Quantum’s renewable energy presence by developing and owning wind and solar farms, as well as manufacturing high-efficiency solar modules. Quantum’s customers include automotive OEMs, fleets, dealer networks, the aerospace industry, and military and other government entities.
For further information about the company, visit www.qtww.com
Yucheng Technologies Ltd. (YTEC) Posts Q4, FY 2011 Financial Results
Yucheng Technologies, a leading provider of IT solutions to the financial services industry in China, today announced its unaudited financial results for the fourth quarter and full year ended December 31, 2011, reflecting better-than-expected revenue growth for 2011.
The company reported fourth quarter 2011 total revenues of $29.6 million, an increase of 35.1 percent year-over-year and an increase of 55.1 percent sequentially. Total revenues for full year 2011 were $77.1 million, an increase of 26.5 percent year-over-year.
Gross margin for the fourth quarter of 2011 was 42.8 percent, compared to 50.7 percent in the prior year period and 49.7 percent in the previous quarter. Gross margin in 2011 was 47.0 percent, compared to 48.8 percent in 2010.
Fourth quarter 2011 net income was $3.5 million, or $0.17 per diluted share, compared to a net loss of $1.6 million, or $(0.08) per diluted share in the prior year period. The company reported full year 2011 net income of $7.1 million, or $0.36 per diluted share, compared to $0.3 million, or $0.02 per diluted share in 2010.
As of December 31, 2011, Yucheng reported cash and cash equivalents and restricted cash totaling $32.5 million, compared to $18.7 million as of September 30, 2011, and $24.5 million as of December 31, 2010.
Operating cash flow in 2011 was a net inflow of $6.6 million.
“We concluded the fiscal year 2011 with another quarter of solid results. We achieved better revenue growth in 2011 than we originally forecasted at the beginning of the year. Looking back over the past two years, we have made steady improvements in management of our operations and turned the company towards positive growth, which is demonstrated by the excellent execution of our operations for eight consecutive quarters,” Weidong Hong, CEO of Yucheng stated in the press release. “Building upon the No. 1 position in the industry, we are committed to further improving our operations and expanding the market share. We look forward to continuing the quarter over quarter of excellent execution to deliver solid and sustainable financial results.”
For more information visit www.yuchengtech.com
AUXILIO, Inc. (AUXO) is “One to Watch”
AUXILIO is a brilliant company with a strong lead as a true pioneer in Managed Print Services (MPS), specifically for the healthcare industry. With a solid focus on the true bottom line, client retention, AUXO boasts an impressive 100% retention rate among hospital partnerships, thanks in large part to the company’s rigorousness in the ferreting out of hidden costs and MPS process inefficiencies.
With print volume reduction programs and key Centers of Excellence, staffed with professional print strategy consultants to devise unparalleled solutions for the requirements of each individual client, the company’s laser-focus on nurturing client caregiver efficiency is only made all the bolder by a continuing commitment to the environment through eco-friendly/e-waste initiatives.
A streamlined and integrated approach to managing/monitoring vital processes in copy, print, and scan infrastructures is provided when AUXILIO steps in. The complex landscape of requirements is solved and the company’s team of experts goes to work; individual hospital units control the purchase and lease of hardware, IT/material management personnel handle supplies, while clinical units handle testing of CAT and MRI functionality/output. The result is a streamline “best use system” that solves the difficult cost equation for profit and usability.
The remarkable cost efficiencies AUXO is able to produce are the result of a firm, hands-on approach developed by the company during its rise to prominence. Indeed, the hallmark of excellence for which AUXO is most widely known is this keen ability to bring high-resolution transparency to the entire spectrum of staff productivity.
As a standard bearer within the industry for cost containment, vendor management, and process refinement, the company strives to apply its well-developed business model, working hand-in-hand with hospital executives to obtain the optimum cost containment envelope for a given operation. There are no upfront fees or unseen risks down the line, only predictable costs and real consistency ensuring the quality of end-user experiences/overall quality of patient care.
Recently, AUXO has seen enthusiasm from the industry in the form of major deals like the recent $40M, five-year contract with Catholic Health East (CHE) to roll out its impressive MPS solutions across 19 CHE facilities. An announcement which quickly followed the $5M, five-year, Memorial Health System (Colorado Springs, CO) agreement from the day before.
The reputation amassed thus far speaks volumes, as healthcare providers turn to AUXO to help shore up costs, confident in the company’s ability to provide intelligent MPS solutions within a risk-free environment where savings are guaranteed. Assuming all print business environment costs via its highly adaptive, customized service integration platform, AUXO is able to stabilize rates at fixed levels unmatched in the industry. As the company continues to innovate, the clients in AUXO’s portfolio of some 1,300 or more U.S. hospitals will continue to benefit.
For more information on this company, or to stay up to date on the latest news and information, please visit AUXILIO’s website at: www.AuxilioInc.com
GWIV is “One to Watch”
GlobalWise Investments, via wholly-owned subsidiary Intellinetics, Inc., is a leading-edge technology company focused on Enterprise Content Management (ECM) solutions for the digital age. The ECM industry continues to grow rapidly as a result of unrestricted proliferation of digital content within today’s business environment. Leveraging its proprietary cloud-based computing software, GlobalWise is poised to capture a significant market share of this burgeoning industry.
GlobalWise’s ECM service is delivered to customers via five unique delivery models which cover the spectrum of business needs: Cloud/Saas (Software as a Service), Hardware Vendor Integrated Service, Software Vendor Integrated Service, Premise (Client-Server), Hybrid (Premise & Cloud/Saas).This diversity gives advanced security & privacy features with an on-demand structure needed for large Tier 3 and Tier 4 businesses that are currently underserved by the market.
The Intellinetics platform defines a new industry benchmark and game-changing approach by combining advanced virtualization & automated content management with an open and service-oriented architecture using web services. The company provides strategies, tactics, and technologies used to manage paper and digital assets from capture to long-term archive, without the need for manual processes conducted by a full time employee.
GlobalWise’s management boasts a combined total of over 60 years in ECM leadership and industry experience. The ECM industry is expected to exceed $5.1 billion by 2013 with Gartner predicting a compound annual growth rate of 9.5%. IBM Market Insights predicts adoption of cloud computing to grow by 26% CAGR between 2010 through 2013. Leveraging management and key department heads, Intellinetics has a strong foundation from which to capture significant market share within the lucrative $149 billion Business Software & Services industry.
Key Investment Highlights
• Cutting-Edge Solutions that Increase Productivity and Cut Costs
• ECM Industry Expected to Exceed $5.7 Billion by 2014 with 10.1% CAGR
• Industry’s First ECM App Store to Drive Mobility Usage and Capability
• Market Leader with Proprietary Software and Experienced Management
CommerceTel Corp. (MFON) Mobile Technology Now Used in Over 3,000 Locations
CommerceTel Corp., an leading provider of proprietary mobile marketing technologies and solutions, announced today that its mobile marketing technology is being used by local advertisers in more than 3,000 locations across the U.S.
CommerceTel’s cloud-based mobile advertising platform enables local and national business owners to increase sales and customer engagement at a fraction of the cost of newspaper, radio, online, and outdoor ads. Customers have found the service to be flexible and highly effective, with more than 97% renewing their initial contracts. In the past twelve months alone, the net number of active local advertiser locations using CommerceTel’s mobile marketing solutions increased by approximately 255%.
“We are extremely excited to deploy our technologies in over 3,000 of our customers’ locations,” stated Dennis Becker, CEO of CommerceTel.” It demonstrates our value proposition and ability to quickly sign and activate new customers. In the past three months alone, we have successfully activated over 325 new clients with a combined 746 locations across the country. With over 560,000 retail restaurant and foodservice locations in the U.S. alone, we have significant greenfield opportunities ahead.”
CommerceTel’s long list of customers include CNN, Disney, Sony Pictures, AT&T, Verizon, USA Network, numerous professional sports franchises, the Golf Channel, and NBC Universal, to name a few. For more information on the company, visit www.commercetel.com
GlobalWise Investments, Inc. (GWIV) Finalizes Intellinetics Acquisition
Today before the opening bell, GlobalWise Investments, Inc. announced the completion of its acquisition of Intellinetics, Inc. (www.Intellinetics.com). Intellinetics is now a wholly owned subsidiary of GlobalWise Investments.
Intellinetics is a leading-edge technology company focused on Enterprise Content Management (ECM) solutions for the digital age. Leveraging its cloud-based computing software, GlobalWise Investments is poised to capture a significant market share of the burgeoning ECM industry.
The Intellinetics platform combines advanced virtualization and automated content management with an open and service-oriented architecture using Web services. The company provides strategies, tactics and technologies to manage paper and digital assets from capture to long-term archive, without the need for manual processes conducted by a full-time employee.
The company’s ECM service is delivered to customers via five unique delivery models that cover the full spectrum of business needs: Cloud/SaaS (Software as a Service); Hardware Vendor Integrated Service; Software Vendor Integrated Service; Premise (Client-Server); and Hybrid (Premise & Cloud/SaaS). This diversity provides advanced security and privacy features with an on-demand structure for businesses in the large, underserved Tier 3 and Tier 4 markets.
William J. “BJ” Santiago, President and CEO of GlobalWise Investments, stated, “IBM Market Insights predicts adoption of cloud computing to continue growing at a compound annual growth rate of 26% until 2013. Through its acquisition of Intellinetics, GlobalWise Investments is well positioned to secure a strong foothold in this rapidly growing ECM industry.”
For more information, please visit www.GlobalWiseInvestments.com
VistaGen Therapeutics (VSTA) Selects Top 10 Candidates for Stem Cell Technology-Based Drug Rescue Programs
VistaGen Therapeutics, Inc., a biotechnology company applying stem cell technology for drug rescue and cell therapy, today announced the identification of its initial Top 10 drug rescue candidates. The company plans to launch two formal drug rescue programs by the end of next quarter.
VistaGen’s goal for each of its stem cell technology-based drug rescue programs is to generate and license a new, safer variant of a once-promising large market drug candidate previously discontinued by a pharmaceutical company no earlier than late-preclinical development.
“We are now at an advanced stage in our business model,” stated Shawn Singh, VistaGen’s Chief Executive Officer. “After more than a decade of focused investment in pluripotent stem cell research and development, we are now at the threshold where game-changing science becomes therapeutically relevant to patients and commercially relevant to our shareholders. We have positioned our company and our stem cell technology platform to pursue multiple large market opportunities. We plan to launch two drug rescue programs by the end of the next quarter.”
Over the past year, VistaGen, working with its network of strategic partners, identified over 525 once-promising new drug candidates that meet the Company’s preliminary screening criteria for heart toxicity-focused drug rescue using CardioSafe 3D™, its human heart cell-based bioassay system. After internally narrowing the field to 35 compounds, VistaGen, working together with its external drug rescue advisors, including former senior pharmaceutical industry executives with drug safety and medicinal chemistry expertise, analyzed and carefully narrowed the group of 35 to the current Top 10.
For more information, please visit www.VistaGen.com
AdCare Health Systems, Inc. (ADK) Refined Strategy Driving Rapid Growth
Relatively few of the most successful business are at the place they are because they came up with a totally new concept or industry. In almost every case, a company is successful because it has simply developed a better way of operating, filling an established need more efficiently than anyone else, bringing a new idea to an existing table.
In the case of AdCare Health Systems, a fast growing developer, owner, and operator of skilled nursing and assisted living communities, success has been based on identifying, acquiring, and transforming existing care facilities, pointing them in a more profitable direction, and incorporating more efficient operations. AdCare realized early-on that the healthcare facilities industry was highly fragmented, made up of largely family owned businesses, generally inefficiently run and weighted toward long-term low-margin markets. On the other hand, they realized that there was a growing need for acute-care high-margin facilities, a need that was not being met.
Through a carefully developed and managed strategy, AdCare has been able to steadily locate and aggressively acquire existing care facilities with just the right mix of needs and location. The company then applies a methodic plan, specifically attuned to the unique assets and requirements of each opportunity, to gradually reposition the operations to higher margin markets while streamlining internal procedures. The result has been a financial engine of increasing revenues and geographical expansion.
In their recent presentation at the 22nd Annual Global Healthcare Services Conference in New York, the company indicated that, with the recent acquisition of a skilled nursing and assisted living community in Ohio, plus 24 additional skilled nursing centers they expect to close in the first quarter of 2012, and the Abington Place skilled nursing facility in Q2 2012, the company expects its annualized revenue run-rate to exceed $355 million, which would represent an increase of 570% over revenues in 2010.
For additional information, visit the company’s website at www.AdCareHealth.com
Mixed Signals From Key Economic Indicators
In case you haven’t guessed, one of the most popular activities for the past several months has been the search for a bottom to the seemingly endless global recession. It was easier in the past. A few national indicators would begin to pick up, and you knew the economy was finally on the upswing. But that’s all changed now. Today the U.S. is locked in a complex economic dance with Europe, China, Japan, and the rest of the world. With so many new variables, clear signals in any given direction are hard to come by. Add to this the fact that unmet expectations can make an outwardly straight-forward signal considerably less clear, turning positives into negatives.
According to the Commerce Department, U.S. retail sales advanced in January, what would normally be considered a healthy sign following what is now being called a relatively flat December. But few cheers were heard because the increase was less than some had expected. Moreover, part of the increase came in the form of higher prices being paid at the gas pump. Nevertheless, even after the price of gasoline is removed, retail sales still saw healthy growth, signaling the beginning of a positive 2012 to some forecasters.
However, another dampening factor is the continuing European crisis, with Moody’s now lowering its ratings on Italy, Spain, and Portugal. As America’s major trading partner, Europe affects U.S. exporters, multinational companies, and ultimately every American. What happens in Europe definitely doesn’t stay in Europe.
And then there’s oil. The price of oil has apparently begun to reverse earlier declines. But what would normally be seen as a gauge of possible economic growth now comes with an enormous amount of baggage. Instead of reflecting positive activity, it is linked with growing tensions between Iran, Israel, the U.S., and Europe. Clearly any disruption in the flow of oil from the Persian Gulf could lead to major jumps in the price of oil all over the world. And high oil prices could easily set back any meager progress being made in Europe, which in turn would affect the U.S.
No matter what metrics you use, the interpretation is increasingly mixed and less meaningful for forecasting. The fact is that key economic indicators just aren’t as key as they used to be.
VistaGen Therapeutics (VSTA) Selects Top 10 Candidates for Stem Cell Technology-Based Drug Rescue Programs
VistaGen Therapeutics, Inc., a biotechnology company applying stem cell technology for drug rescue and cell therapy, today announced the identification of its initial Top 10 drug rescue candidates. The company plans to launch two formal drug rescue programs by the end of next quarter.
VistaGen's goal for each of its stem cell technology-based drug rescue programs is to generate and license a new, safer variant of a once-promising large market drug candidate previously discontinued by a pharmaceutical company no earlier than late-preclinical development.
"We are now at an advanced stage in our business model," stated Shawn Singh, VistaGen's Chief Executive Officer. "After more than a decade of focused investment in pluripotent stem cell research and development, we are now at the threshold where game-changing science becomes therapeutically relevant to patients and commercially relevant to our shareholders. We have positioned our company and our stem cell technology platform to pursue multiple large market opportunities. We plan to launch two drug rescue programs by the end of the next quarter."
Over the past year, VistaGen, working with its network of strategic partners, identified over 525 once-promising new drug candidates that meet the Company's preliminary screening criteria for heart toxicity-focused drug rescue using CardioSafe 3D™, its human heart cell-based bioassay system. After internally narrowing the field to 35 compounds, VistaGen, working together with its external drug rescue advisors, including former senior pharmaceutical industry executives with drug safety and medicinal chemistry expertise, analyzed and carefully narrowed the group of 35 to the current Top 10.
VSTA Selects Top 10 Candidates for Stem Cell Technology-Based Drug Rescue Programs
VistaGen Therapeutics, Inc., a biotechnology company applying stem cell technology for drug rescue and cell therapy, today announced the identification of its initial Top 10 drug rescue candidates. The company plans to launch two formal drug rescue programs by the end of next quarter.
VistaGen's goal for each of its stem cell technology-based drug rescue programs is to generate and license a new, safer variant of a once-promising large market drug candidate previously discontinued by a pharmaceutical company no earlier than late-preclinical development.
"We are now at an advanced stage in our business model," stated Shawn Singh, VistaGen's Chief Executive Officer. "After more than a decade of focused investment in pluripotent stem cell research and development, we are now at the threshold where game-changing science becomes therapeutically relevant to patients and commercially relevant to our shareholders. We have positioned our company and our stem cell technology platform to pursue multiple large market opportunities. We plan to launch two drug rescue programs by the end of the next quarter."
Over the past year, VistaGen, working with its network of strategic partners, identified over 525 once-promising new drug candidates that meet the Company's preliminary screening criteria for heart toxicity-focused drug rescue using CardioSafe 3D™, its human heart cell-based bioassay system. After internally narrowing the field to 35 compounds, VistaGen, working together with its external drug rescue advisors, including former senior pharmaceutical industry executives with drug safety and medicinal chemistry expertise, analyzed and carefully narrowed the group of 35 to the current Top 10.
GlobalWise Investments, Inc. (GWIV) Finalizes Intellinetics Acquisition
Today before the opening bell, GlobalWise Investments, Inc. announced the completion of its acquisition of Intellinetics, Inc. (www.Intellinetics.com). Intellinetics is now a wholly owned subsidiary of GlobalWise Investments.
Intellinetics is a leading-edge technology company focused on Enterprise Content Management (ECM) solutions for the digital age. Leveraging its cloud-based computing software, GlobalWise Investments is poised to capture a significant market share of the burgeoning ECM industry.
The Intellinetics platform combines advanced virtualization and automated content management with an open and service-oriented architecture using Web services. The company provides strategies, tactics and technologies to manage paper and digital assets from capture to long-term archive, without the need for manual processes conducted by a full-time employee.
The company’s ECM service is delivered to customers via five unique delivery models that cover the full spectrum of business needs: Cloud/SaaS (Software as a Service); Hardware Vendor Integrated Service; Software Vendor Integrated Service; Premise (Client-Server); and Hybrid (Premise & Cloud/SaaS). This diversity provides advanced security and privacy features with an on-demand structure for businesses in the large, underserved Tier 3 and Tier 4 markets.
William J. “BJ” Santiago, President and CEO of GlobalWise Investments, stated, “IBM Market Insights predicts adoption of cloud computing to continue growing at a compound annual growth rate of 26% until 2013. Through its acquisition of Intellinetics, GlobalWise Investments is well positioned to secure a strong foothold in this rapidly growing ECM industry.”
GWIV Finalizes Intellinetics Acquisition
Today before the opening bell, GlobalWise Investments, Inc. announced the completion of its acquisition of Intellinetics, Inc. (www.Intellinetics.com). Intellinetics is now a wholly owned subsidiary of GlobalWise Investments.
Intellinetics is a leading-edge technology company focused on Enterprise Content Management (ECM) solutions for the digital age. Leveraging its cloud-based computing software, GlobalWise Investments is poised to capture a significant market share of the burgeoning ECM industry.
The Intellinetics platform combines advanced virtualization and automated content management with an open and service-oriented architecture using Web services. The company provides strategies, tactics and technologies to manage paper and digital assets from capture to long-term archive, without the need for manual processes conducted by a full-time employee.
The company’s ECM service is delivered to customers via five unique delivery models that cover the full spectrum of business needs: Cloud/SaaS (Software as a Service); Hardware Vendor Integrated Service; Software Vendor Integrated Service; Premise (Client-Server); and Hybrid (Premise & Cloud/SaaS). This diversity provides advanced security and privacy features with an on-demand structure for businesses in the large, underserved Tier 3 and Tier 4 markets.
William J. “BJ” Santiago, President and CEO of GlobalWise Investments, stated, “IBM Market Insights predicts adoption of cloud computing to continue growing at a compound annual growth rate of 26% until 2013. Through its acquisition of Intellinetics, GlobalWise Investments is well positioned to secure a strong foothold in this rapidly growing ECM industry.”
Celsion Corp. (CLSN) Enrolls First Patient in Phase II Study for Colorectal Liver Metastases Treatment
Leading oncology drug development company Celsion Corp. today announced it has enrolled its first patient in a randomized phase II study of ThermoDox, the company’s lead product candidate. ThermoDox is a heat-activated liposomal encapsulation of doxorubicin that, in combination with radiofrequency ablation (RFA), is being tested for the treatment of colorectal liver metastases (CRLM).
Up to 88 patients diagnosed with colorectal cancer metastasized to the liver are expected to be enrolled in the multicenter phase II study. The patients will be randomized to receive liver tumor treatment that is either includes RFA plus ThermoDox or RFA alone. Leading North American research institutions will be included in the phase II study, including Montefiore-Einstein Center for Cancer Care in New York City, which is where Lead Principal Investigator Dr. Steven K. Libutti serves as director.
More than 141,000 new cases of colorectal cancer were diagnosed in 2010, with 51,000 colorectal cancer deaths, according to the American Cancer Society. As many as 25 percent of colorectal cancer patients present with liver metastases, and 50 percent develop liver metastases within five years. The liver provides a favorable environment for growth and proliferation of metastases for cancers of the colon and rectum, and addressing these metastases enables improvement of three- and five-year survival rates for patients with this type of cancer. RFA alone is often limited to treating smaller metastases within the liver, but the addition of ThermoDox as adjuvant therapy has shown early clinical promise in treating larger tumors and multifocal disease. The primary endpoint of the phase II study is based on one year local tumor recurrence, with secondary endpoints of time to progression and overall survival.
Celsion Corp. is a leading oncology company specializing in the development and commercialization of cancer drugs. Celsion has research, license and commercialization agreements with such leading institutions as the National Institutes of Health, Duke University, University of Hong Kong, UCLA Department of Medicine, the University of Pisa, Kyungpook National University Hospital, and the Beijing Cancer Hospital.
For further information about the company, visit www.celsion.com
VistaGen Therapeutics (VSTA) Helps Big Pharma Take Better Aim
An increasingly important word in drug development today is focus, the ability to understand the genetic makeup of a target patient population so that the hyper-expensive process of discovering and developing drugs will have an improved chance of hitting the mark. Such focus has become a corporate strategy for big pharma companies like Roche. The company has made diagnostics a key aspect of its in-house investments as well as for its evaluation of possible acquisitions. Roche’s CEO, Severin Schwan, said as much in a recent interview, indicating that they were specifically targeting companies with strong diagnostic technologies. In January, Roche offered $5.7 billion for Illumina, seeking technology for identifying the genetic makeup of tumors.
The idea is to develop drugs that are so patient-focused, both effective and free of any latent toxicity potential, that the marketplace will find them compelling. Considering that the cost of developing and bringing a new drug to market can top a billion dollars, the importance of knowing everything possible about the drug/patient interaction is more important than ever.
VistaGen Therapeutics holds a unique position in the growing movement for better focus in drug development. The company uses advanced stem cell technology to produce functional human cells, such as heart cells, allowing drug developers to perform highly accurate early-stage testing on human cells, even before animal testing, of new drug candidates for cardiotoxicity so there are no surprises down the road. By attacking potential issues early in the cost curve, the result is better targeting of resources and huge potential savings for developers, and ultimately the healthcare system, by reducing the risk of developing a drug that could later be recalled. Cardiotoxicity, for example, has been a factor in nearly 30% of U.S. drug withdrawals, costing drug developers billions of dollars in potentially avoidable losses.
For additional information, visit the company’s website at www.VistaGen.com
Limelight Networks, Inc. (LLNW), IMJ and Panasonic Create IP Broadcasting Service
Limelight Networks, Inc. recently announced that Limelight has created a new IPTV service with IMJ Corp. and Panasonic Network Services. The service was created for Tsutaya TV, an electronic video delivery service in Japan that broadcasts live events to smart televisions.
Limelight is focused on creating software solutions that help businesses profit from online content and advertising through marketing/test marketing as well as monetizing online and digital content.
The first live show broadcast via Tsutaya TV was “HARAJUKU KAWAii!!!!,” featuring fashion, culture, and music for young girls, and aired on December 28 of 2011. IMJ supplied systems software and management for the project, while Panasonic provided software, which included DRM (digital rights management) via Marlin DRM. Limelight supplied the infrastructure for the content delivery system. The event was capable of hosting 2000 simultaneous connections with full HD via Internet-connected smart TVs. Limelight’s technology is scalable to serve up to 10,000 simultaneous users.
“IMJ is proud to lead the development of this innovative service for Tsutaya TV users,” said Nariaki Hatta, Senior Producer, New Business Development, Broadband Division of IMJ Corporation. “Live event delivery to connected devices is a unique experience that IMJ and our partners bring to Tsutaya and their users. The build-out demonstrates how integration at all levels can bring innovative new services to customers. Partners like Limelight enable us to offer our customers state-of-the-art services that leverage content delivery expertise and one of the world’s only truly global CDNs.”
“This project is an important one not only for Tsutaya and their Japanese customers, but to the industry,” said Andrew Clark, Vice President, Asia Pacific Sales and Operations for Limelight Networks Japan KK. “In partnership with IMJ and PNS, Tsutaya is now able to deliver highly scalable, high quality, HD IPTV live events on demand. This type of service opens up revenue streams based on new Live-to-the-TV events for Tsutaya and other content providers in the future.”
Clean Diesel Technologies, Inc. (CDTI) Receives Expanded California Approval for Emissions Reduction System
Clean Diesel Technologies is a global manufacturer and distributor of emissions control systems and products focused on the heavy duty diesel and light duty vehicle markets. One of the company’s main products is its ECS purifilter brand emission reduction product.
The company today announced that the California Air Reources Board (CARB) has expanded their approval of Clean Diesel’s ECS Purifilter emission reduction product to now include larger control devices aimed at heavy duty on-road vehicle engines up to 16 liters and 625 horsepower. This market will include not only heavy duty trucks, but also municipal vehicles as well as school buses.
This approval is a key development for the company. It further increase the number of vehicle engines that the company is approved to retrofit. Clean Diesel estimates that a CARB regulation will require well over 100,000 heavy duty diesel trucks to either be replaced or retrofitted over the next few years.
The CARB regulation applies to a variety of diesel-fueled trucks and buses. Its purpose is to reduce emissions from in-use trucks and buses in order to meet federally mandated clean air standards and to reduce the adverse health effects from truck and bus pollution. The mandate requires all heavier 1996 to 2006 vehicles (over 26,000 pounds) be retrofitted with diesel particulate filters.
For more details on CARB regulations, visit its website at www.arb.ca.gov
And for more information about Clean Diesel Technologies and its emission reduction products, please visit the company’s website at www.cdti.com
Clean Diesel Technologies, Inc. (CDTI) Receives Expanded California Approval for Emissions Reduction System
Clean Diesel Technologies is a global manufacturer and distributor of emissions control systems and products focused on the heavy duty diesel and light duty vehicle markets. One of the company’s main products is its ECS purifilter brand emission reduction product.
The company today announced that the California Air Reources Board (CARB) has expanded their approval of Clean Diesel’s ECS Purifilter emission reduction product to now include larger control devices aimed at heavy duty on-road vehicle engines up to 16 liters and 625 horsepower. This market will include not only heavy duty trucks, but also municipal vehicles as well as school buses.
This approval is a key development for the company. It further increase the number of vehicle engines that the company is approved to retrofit. Clean Diesel estimates that a CARB regulation will require well over 100,000 heavy duty diesel trucks to either be replaced or retrofitted over the next few years.
The CARB regulation applies to a variety of diesel-fueled trucks and buses. Its purpose is to reduce emissions from in-use trucks and buses in order to meet federally mandated clean air standards and to reduce the adverse health effects from truck and bus pollution. The mandate requires all heavier 1996 to 2006 vehicles (over 26,000 pounds) be retrofitted with diesel particulate filters.
For more details on CARB regulations, visit its website at www.arb.ca.gov
And for more information about Clean Diesel Technologies and its emission reduction products, please visit the company’s website at www.cdti.com
PositiveID (PSID) Achieves Positive Preliminary Results for Glucose-sensing Diabetes Device
PositiveID Corp., a developer of medical technologies for diabetes management, today announced that preliminary results from its biotransport research study with the Diabetes Research Institute (DRI) at the University of Miami demonstrate positive data for the company’s GlucoChip ™.
PositiveID’s GlucoChip is a glucose-sensing implantable microchip, currently under development with RECEPTORS LLC, for individuals with diabetes. The company reports that preliminary results demonstrate that the membrane materials to be used with GlucoChip allow for successful movement of glucose from body fluids.
“These first studies were successfully completed with the demonstration that a glucose tracer readily enters the device from surrounding body fluids. We are currently implementing the next phase of these studies, which will focus in more detail on both the kinetics of transport, which will determine how quickly the device will be able to respond to changes in glucose levels in the body, and on the long-term biocompatibility of the membrane,” Robert E. Carlson, Ph.D., RECEPTORS president and chief scientific officer stated in the press release.
PositiveID chairman and CEO William J. Caragol said by achieving the positive results, the company is on-track to overcoming “significant” development challenges.
“We believe the preliminary results from our research study at the DRI are not only positive but also promising as we proceed with our development. By achieving early confirmation that the membrane materials we will use with GlucoChip allow for movement of glucose from fluids in the body into the glucose-sensing device, we have begun to eliminate one of the significant hurdles of this potentially ground-breaking development project,” Caragol stated.
PositiveID and partner RECEPTORS LLC have completed prototype development of a stable and reproducible, closed-cycle continuous glucose-sensing system. Should they achieve continued positive results from the biocompatibility and biotransport, PositiveID will be on-track to complete development of GlucoChip.
For more information visit www.PositiveIDCorp.com